Your browser doesn't support javascript.
loading
Prescribed exercise regimen versus usual care and hypochlorous acid wound solution versus placebo for treating venous leg ulcers: study protocol for a randomised controlled trial (Factorial4VLU).
Jull, Andrew; Wadham, Angela; Bullen, Chris; Parag, Varsha; Parsons, John G M; Laking, George; Waters, Jill; Klonizakis, Markos; O'Brien, Jane.
Afiliación
  • Jull A; School of Nursing, University of Auckland, Auckland, New Zealand a.jull@auckland.ac.nz.
  • Wadham A; National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.
  • Bullen C; National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.
  • Parag V; National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.
  • Parsons JGM; National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.
  • Laking G; School of Nursing, University of Auckland, Auckland, New Zealand.
  • Waters J; Blood and Cancer Directorate, Auckland District Health Board, Auckland, New Zealand.
  • Klonizakis M; Hope Foundation for Research on Ageing, Auckland, New Zealand.
  • O'Brien J; Centre for Sport and Exercise Science, Sheffield Hallam University, Sheffield, UK.
BMJ Open ; 11(2): e043420, 2021 02 18.
Article en En | MEDLINE | ID: mdl-33602710
INTRODUCTION: Compression is the mainstay of treatment for venous leg ulcers (VLUs) and there are few effective adjuvant treatments. There is only observational evidence supporting the use of hypochlorous acid (HOCl) as a topical wound solution on VLU and some limited randomised evidence for the effect of a prescribed regimen of exercise. METHODS AND ANALYSIS: The Factorial4VLU trial is a pragmatic, blinded, factorial randomised controlled trial, with 380 participants receiving either a prescribed exercise regimen compared with usual care and either active HOCl wound solution or placebo wound solution at each dressing change for up to 24 weeks. All participants will receive compression therapy. The primary outcome is the proportion of participants with healed VLU at 12 weeks after randomisation as adjudicated by blinded review of ulcer photographs. Secondary outcomes are proportion healed at 24 weeks, time to healing, estimated change in ulcer area, change in 2-Minute Walk Test, change in health-related quality of life, incidence of infection and incidence of all-cause adverse events. If either of the interventions shows a statistically significant positive difference on healing outcomes, cost-effectiveness will be modelled using a health service perspective. ETHICS AND DISSEMINATION: The Factorial4VLU trial received ethical approval from the Northern B Health and Disability Ethics Committee. We plan to publish the results within 1 year of trial completion and will include the results on the trial registration page. TRIAL REGISTRATION NUMBERS: Australia and New Zealand Clinical Trials Register (http://www.anzctr.org.au) (ACTRN12620000116921); Universal Trial Number (WHO) (U1111-1236-2997).
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Úlcera Varicosa / Ácido Hipocloroso Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Ethics / Patient_preference Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: BMJ Open Año: 2021 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Úlcera Varicosa / Ácido Hipocloroso Tipo de estudio: Clinical_trials / Prognostic_studies Aspecto: Ethics / Patient_preference Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: BMJ Open Año: 2021 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Reino Unido